MIRA Pharmaceuticals, Inc.
MIRAHealthcare|Drug Manufacturers - General|US
$0.57
+0.03 (+5.61%)
DCF Value
$0.26
Tangible Book / Share
$0.19
Cash / Share
$0.19
Financials
Financial Snapshot
Market Cap
$24.0M
Enterprise Value
$20.4M
Revenue (TTM)
$0.00
Net Income (TTM)
-$9.5M
Cash & Investments
$8.1M
Net Cash
$8.1M
Free Cash Flow (TTM)
-$4.6M
Operating CF (TTM)
-$4.6M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$8.1M
Quarterly Burn
$1.2M
Monthly Burn
$386.6K
Est. Runway
~7.0 quarters
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $3.5K | $2.8M | $351.0K | $4.6M | $2.8M | $6.3M | $8.1M | |
| Operating Cash Flow | -$68.0K | -$1.4M | -$5.6M | -$4.5M | -$5.6M | -$4.7M | -$4.6M | |
| Free Cash Flow | -$68.0K | -$1.4M | -$5.6M | -$4.5M | -$5.6M | -$4.7M | -$4.6M | |
| Capital Expenditure | $3.00 | $0.00 | $0.00 | $0.00 | -$4.00 | $0.00 | $7.00 | |
| Financing Cash Flow | $71.1K | $4.2M | $3.1M | $8.8M | $3.8M | $8.2M | $7.5M |
R&D Spending
R&D (TTM)
$2.1M
R&D Intensity
—
R&D Growth vs Prior
+24.4%
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $14.6K | $684.4K | $2.4M | $1.6M | $3.3M | $1.7M | $2.1M | |
| SG&A | $53.0K | $770.1K | $3.0M | $6.5M | $4.7M | $8.8M | $7.3M |
Income Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $14.6K | $684.4K | $2.4M | $1.6M | $3.3M | $1.7M | $2.1M | |
| SG&A | $53.0K | $770.1K | $3.0M | $6.5M | $4.7M | $8.8M | $7.3M | |
| Operating Income | -$67.6K | -$2.2M | -$7.0M | -$8.5M | -$8.0M | -$10.5M | -$9.4M | |
| Interest Expense | $364.00 | $24.4K | $10.3K | $3.5M | $165.7K | $0.00 | $0.00 | |
| Pretax Income | -$68.0K | -$2.2M | -$7.1M | -$12.0M | -$7.9M | -$10.4M | -$9.5M | |
| Net Income | -$68.0K | -$2.2M | -$7.1M | -$12.0M | -$7.9M | -$10.4M | -$9.5M | |
| EPS (Diluted) | -0.00 | -0.15 | -0.48 | -0.65 | -0.51 | -1.35 | -1.38 | |
| EBITDA | -$67.6K | $0.00 | $0.00 | -$8.5M | -$8.0M | -$10.4M | -$9.4M | |
| Shares Out. (M) | 14.75 | 14.75 | 14.75 | 18.57 | 15.44 | 23.69 | 42.02 |
Balance Sheet
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.5K | $2.8M | $351.0K | $4.6M | $2.8M | $6.3M | $3.6M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $4.5M | |
| Total Current Assets | $3.5K | $2.9M | $494.4K | $4.9M | $2.9M | $11.1M | $8.2M | |
| Total Assets | $22.4K | $3.4M | $858.1K | $4.9M | $2.9M | $11.1M | $8.2M | |
| Total Current Liabilities | $90.4K | $1.1M | $1.4M | $558.1K | $723.3K | $702.1K | $40.8K | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $90.4K | $1.1M | $1.5M | $558.1K | $723.3K | $702.1K | $40.8K | |
| Stockholders' Equity | -$68.0K | $2.3M | -$596.2K | $4.4M | $2.2M | $10.4M | $8.2M | |
| Retained Earnings | -$68.0K | -$2.2M | -$9.3M | -$21.3M | -$29.1M | -$39.6M | -$41.9M |
Cash Flow Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$68.0K | -$1.4M | -$5.6M | -$4.5M | -$5.6M | -$4.7M | -$4.6M | |
| Capital Expenditure | $3.00 | $0.00 | $0.00 | $0.00 | -$4.00 | $0.00 | $7.00 | |
| Free Cash Flow | -$68.0K | -$1.4M | -$5.6M | -$4.5M | -$5.6M | -$4.7M | -$4.6M | |
| Investing Cash Flow | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $71.1K | $4.2M | $3.1M | $8.8M | $3.8M | $8.2M | $7.5M | |
| Issuance of Stock | $0.00 | $4.5M | $2.9M | $7.7M | $3.6M | $7.9M | -$512.4K | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $90.0K | $203.1K | -$160.0K | $1.0M | $0.00 | $572.9K | -$330.6K | |
| Stock Based Comp. | $0.00 | $0.00 | $1.3M | $2.6M | $1.9M | $6.3M | $5.0M | |
| Net Change in Cash | $3.5K | $2.8M | -$2.5M | $4.3M | -$1.8M | $3.5M | $2.9M |
Dilution Tracker
Shares outstanding grew 60.7% over 5 years — significant dilution
Shares Outstanding
42M
5-Year Share Growth
+60.7%
Stock Issuance (TTM)
-$512.4K
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 14.75 | 14.75 | 14.75 | 18.57 | 15.44 | 23.69 | 42.02 | |
| Change vs Prior % | — | 0.0% | 0.0% | 25.9% | -16.8% | 53.4% | 77.4% | |
| Stock Issuance | $0.00 | $4.5M | $2.9M | $7.7M | $3.6M | $7.9M | -$512.4K | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $1.3M | $2.6M | $1.9M | $6.3M | $5.0M |
Margins & Profitability
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| ROE % | 100.0% | -96.2% | 1183.8% | -273.9% | -357.0% | -100.5% | -107.0% | |
| ROA % | -303.9% | -64.9% | -822.6% | -242.9% | -268.6% | -94.1% | -115.6% | |
| ROIC % | -307.3% | -84.3% | 6712.3% | -194.7% | -364.5% | -101.0% | -115.2% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -3082.3% | -227.5% | -21.0% | 6.0% | -30.9% | |
| Net Income | 0.0% | -3101.1% | -224.3% | -69.8% | 34.5% | -33.0% | |
| EPS (Diluted) | 0.0% | -3160.9% | -220.0% | -35.4% | 21.5% | -164.7% | |
| Operating Cash Flow | 0.0% | -1924.0% | -307.3% | 19.1% | -22.7% | 16.2% | |
| Free Cash Flow | 0.0% | -1924.1% | -307.3% | 19.1% | -22.7% | 16.2% | |
| R&D Expense | 0.0% | 4573.0% | 243.6% | -33.1% | 110.1% | -48.0% | |
| SG&A Expense | 0.0% | 1353.5% | 288.5% | 117.2% | -27.5% | 86.2% | |
| Total Assets | 0.0% | 14897.8% | -74.4% | 474.8% | -40.7% | 279.5% | |
| Book Value / Share | 0.0% | 3425.9% | -126.4% | 682.7% | -39.5% | 207.9% | |
| Debt | 0.0% | 225.6% | 67.6% | -99.0% | -100.0% | 0.0% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 25.9% | -16.8% | 53.4% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B2.94
10Y Low / Med / High3.44 / 8.00 / 41.86
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.26
Tangible Book / Share
$0.19
Net Current Assets / Share
$0.19
Graham Net-Net
$0.19
Cash / Share
$0.19
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -1395.65 | -42.80 | -13.38 | -1.62 | -2.24 | -1.12 | -0.41 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -1392.26 | 41.86 | -158.77 | 4.46 | 8.00 | 3.44 | 2.94 | |
| EV/EBITDA | -1401.03 | 0.00 | 0.00 | -1.75 | -1.84 | -2.82 | -2.16 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
342.59
Safe
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $276.0M | $40.0M | $0.00 |
| Net Income | -$2.8M | -$3.8M | -$4.3M |
| EPS | $-0.12 | $-0.16 | $-0.18 |
| # Analysts (EPS) | 1 | 1 | 1 |